|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: HOLD @ $0.285
Signal Strength: MEDIUM
Cogstate (ASX:CGS) currently has positive Volume MACD of 3418. This means the signal line is greater than the Volume MACD line signalling a bullish movement.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Volume Moving Average Convergence/Divergence (VMACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).
Calculation: Moving Average Convergence Divergence Volume (VMACD):
1) VMACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of VMACD Line;
3) VMACD Histogram: VMACD Line - Signal Line;
PROFILE: Cogstate (CGS.AX)
Stock Exchange: ASX
Ticker Codes: | CGS.AX | ASX:CGS |
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain injury applications primarily in Australia, the United States, and Europe. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of disease and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations. As of June 30, 2017, it had participated in approximately 1,200 academic research studies in approximately 70 indications. The Healthcare segment provides Cognigram, a system that enables regular and standardized assessment of patients to detect cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is headquartered in Melbourne, Australia.
|MOC Mortgage Choice||0.91||14.5||663,230||51,567||BULLISH|
|MPL Medibank Private||3.21||11.5||23,800,298||1,465,447||BULLISH|
|GNG GR Engineering Services||0.95||9.8||41,600||3,433||BULLISH|
|WBC Westpac Banking Corporation||27.75||9.2||24,404,464||1,511,960||BULLISH|
|ALK Alkane Exploration||0.24||9.1||1,447,163||204,688||BULLISH|
|AHG Advance Healthcare||2.55||9||1,585,387||151,695||BULLISH|
|OVH Onevue Holdings||0.49||8.9||426,122||44,553||BULLISH|
|NAB National Australia Bank||25.81||7.9||23,451,421||1,340,497||BULLISH|
|ANZ Australia & Banking||27.86||7.8||14,554,708||867,930||BULLISH|